Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02880111 : Rates DMBT1 ( Glycoprotein) in Sputum of CF Patients With Pseudomonas Aeruginosa
PhaseN/A
AgesMin: 6 Years Max: 35 Years
Eligibility
Inclusion Criteria:

- CF patient 6 to 35 years

- Availability of sputum

- Signed Informed consent

Exclusion Criteria:

- Cardiac insufficiency

- Anti-inflammatory drugs on going

- Oral corticosteroid therapy

- Inhaled corticosteroids during the two weeks before inclusion,

- Patient awaiting lung transplantation

- Patient with a past history of heart/lung transplantation

- Patient with a sputum examination positive for : atypical mycobacteria, Burkholderia
cepacia, Stenotrophomonas maltophilia,

- Patient chronically colonized with multiresistant Pseudomonas aeruginosa

- Inhaled Colymicine® or Tobramycin® during the two weeks before inclusion

- Change of the CF treatment during the last 4 weeks +/- 2 days before inclusion :
corticosteroid, pancreatic extracts, antisecretory drugs...
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02880111      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740